Latest news with #CLIA-waived
Malaysian Reserve
21 hours ago
- Health
- Malaysian Reserve
Molecular Point-of-Care (mPOC) Market Reaches $1.8 Billion: Kalorama Report Spotlights Rapid PCR Innovation and Expanding Frontiers in STI and HAI Testing
ARLINGTON, Va., June 20, 2025 /PRNewswire/ — Kalorama Information, a leading authority in in vitro diagnostics (IVD) market research, has released Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029, estimating the global mPOC market at $1.8 billion in 2024. The report offers a comprehensive forecast through 2029, highlighting transformative opportunities in respiratory, sexually transmitted, and hospital-acquired infection diagnostics at or near the point of care. 'While the molecular point-of-care market saw unprecedented acceleration during the COVID-19 pandemic, Kalorama's latest analysis reveals it now stands on a firmer foundation with renewed growth expected,' said Justin Saeks, senior market analyst and report author. 'We anticipate an almost double-digit compound annual growth rate for the 'true' mPOC segment as demand spreads beyond COVID to broader respiratory panels, STIs, HAIs, and tropical diseases.' Key Findings from the Report: Respiratory testing dominates the market, with COVID-19, flu, strep, and RSV continuing to drive system adoption, particularly for combination tests. Growth expected in HAIs and STIs, although these will evolve more slowly due to testing infrastructure and workflow differences across care settings. 'True' mPOC segment revenues, which had recently declined, are projected to achieve a substantial CAGR from 2024 to 2029. Kalorama differentiates between 'true' mPOC platforms and near-patient systems, offering detailed segmentation by company, region, and disease target. Abbott and Cepheid lead their respective segments. True mPOC Systems: Compact, fast, CLIA-waived (or with waiver potential), and operable by non-lab personnel. Key players include Abbott (market leader), Roche, Cepheid, QuidelOrtho, BioFire, and Sekisui. Near-Patient Molecular Systems: Encompasses larger non-POC systems and smaller platforms with POC or near-POC potential. BioFire and Cepheid are major competitors, with Cepheid leading this segment. Why It Matters Now The report's release is timely as healthcare providers seek diagnostic solutions that balance speed, accuracy, and accessibility across both developed and resource-limited settings. mPOC systems bring the power of molecular testing to emergency departments, outpatient clinics, nursing homes, mobile labs, and even homes—enabling timely treatment decisions and improving care outcomes. 'POC molecular diagnostics represent one of the most important intersections between innovation and access in global health,' said Alisa Alvich, Marketing Director at Science and Medicine Group, Kalorama Information's parent company. 'Kalorama's analysis shows where this market is headed and what players must consider to stay competitive.' Audience Impact This research is essential for: Product Managers and R&D leaders developing decentralized molecular platforms. Corporate strategy teams evaluating new market opportunities or CLIA-waived innovations. Investors and M&A professionals scouting high-growth segments or acquisition targets. Clinical lab and procurement teams optimizing test menus for decentralized care delivery. With deep dives into market sizing, disease applications, regional dynamics, and competitive intelligence, Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029 equips life sciences professionals with the insights needed to navigate a rapidly evolving diagnostics frontier. Get the Report Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029 is now available for purchase at: For purchasing inquiries or to schedule a custom consultation, contact:Sheri Davie – Sales Director, Kalorama About Kalorama Information Kalorama Information, part of Science and Medicine Group Inc., is a trusted publisher of market research exclusively focused on the healthcare industry. For over 25 years, Kalorama has delivered accurate, timely, and strategic intelligence to leaders in biotechnology, clinical diagnostics, in vitro diagnostics (IVD), pharmaceuticals, medical devices, and broader healthcare sectors. Originally launched in 1998, Kalorama Information quickly established itself as a premier source of insight into U.S. and global medical markets. Today, Kalorama remains a leading authority on healthcare market dynamics, with a particular emphasis on IVD. Kalorama is best known for its flagship title, The Worldwide Market for In Vitro Diagnostic Tests, an internationally recognized benchmark in the diagnostics field. Other reports published throughout the year cover these and other healthcare topics in greater detail. Our innovative approach to research, combined with deep industry expertise, has made Kalorama a go-to resource for top healthcare companies, strategic planners, investors, and media seeking authoritative market data and trends. With a singular focus on healthcare, Kalorama continues to shape informed decision-making across the industry through comprehensive, evidence-based analysis. Kalorama also works in coordination with other Science and Medicine Group brands, including BioInformatics, which focuses on life science markets and marketing, SDi, the leading source of information on the laboratory life science and analytical instrumentation industry and publisher of IBO, its twice-monthly newsletter, and IMV, which publishes reports and data on the medical imaging and clinical markets. For more information about Kalorama Information and other services offered by Science and Medicine Group, please visit our website.
Business Wire
30-04-2025
- Health
- Business Wire
binx health and WellStreet Urgent Care Increase Access to Chlamydia and Gonorrhea Testing and Care In-clinic
BOSTON--(BUSINESS WIRE)--binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, today announced a new partnership with WellStreet Urgent Care, a leading healthcare provider based in Atlanta, Georgia. WellStreet Urgent Care is taking steps to improve the way patients access sexually transmitted infection ('STI') treatment and care through advanced Point-of-Care ('POC') technologies throughout WellStreet Urgent Care locations. The program is powered by the binx io, an FDA-cleared, CLIA-waived, molecular PCR chlamydia and gonorrhea ~30-minute test for male and female patients. Together, WellStreet Urgent Care and binx health are redefining diagnostic access by providing patients and providers an avenue for same day test and treatment all in-clinic. With the launch of this program at 115 locations across WellStreet brands such as Piedmont, Corewell Health Urgent Care, Prisma Health and University Hospitals, WellStreet Urgent Care aims to reduce the barriers and challenges associated with traditional STI testing pathways. Today, patients are waiting on average 24-72 hours for a chlamydia and gonorrhea test result. This time lag can result in delayed or unnecessary treatment and further infection spread while increasing patient anxiety. 1, 2 With the binx io, WellStreet Urgent Care will provide patients PCR reference lab-comparable results in the same patient visit, setting a new standard for patient care. WellStreet's Chief Operating and Medical Officer, Michael Duchynski, MD, MBA, said, 'In urgent care, we often only get one opportunity to diagnose and treat our patients, and providing same-day testing, results, and treatment has a profound impact on patient outcomes. With the ability to test, receive results, and begin treatment all in one visit, we're not only improving patient satisfaction but also significantly enhancing the speed, quality, and effectiveness of care.' STIs continue to pose a significant public health challenge, highlighting the need for new technologies geared at prevention and early detection. According to the Centers for Disease Control and Prevention (CDC) chlamydia and gonorrhea prevail as the two most common STIs with over 2 million cases in the U.S annually. 3 These infections can be asymptomatic and if left untreated, can lead to long-term complications including infertility, chronic pelvic pain and increased susceptibility to other infections. 4, 5 POC platforms like the binx io, make routine testing accessible and help to mitigate these negative health outcomes. "Partnering with binx health to offer same-day molecular PCR testing and subsequent specific treatment for Chlamydia and Gonorrhea is critical,' said Brian S. Bobb, M.D., Senior Medical Officer, SVP at WellStreet Urgent Care. 'By integrating this advanced testing technology into our clinics, we're not only enhancing operational efficiency, but, more importantly, improving patient care by reducing wait time and anxiety. Diagnoses that used to take days to determine can now be confirmed via this seamless, one-visit approach, allowing us to provide timely, effective care while minimizing the risk of further transmission or complications. It's a vital step toward delivering higher-quality, more accessible healthcare for our communities.' Through a same day test and treat model, WellStreet Urgent Care and binx health are empowering individuals to take control of their sexual health in a way that is convenient, discreet, and affordable. 'Binx is incredibly proud to partner with WellStreet to bring POC male and female STI testing to their facilities throughout the US,' added binx Health President, Mike Karsonovich. 'Urgent Cares play an integral role in how communities access healthcare and we at binx are very excited to play a part in helping WellStreet to improve patient access to such important sexual health diagnostics and care.' Individuals within Georgia, Ohio and South Carolina can access same-day chlamydia and gonorrhea testing at participating WellStreet Urgent Care locations. Information on participating locations and prospective patient information can be found by visiting About WellStreet Urgent Care Founded in 2011 in Atlanta, Georgia, WellStreet Urgent Care began as an independent operator and quickly expanded to a network of seven locations within its first year. In 2014, WellStreet pioneered its partnership model, joining forces with Piedmont Healthcare to extend the Piedmont Urgent Care brand across North Georgia. This model continued to evolve in 2019 when WellStreet partnered with Beaumont, now Corewell Health, to operate a network of urgent care centers in Southeastern Michigan. Further expanding its reach, WellStreet entered into new partnerships in early 2023 with University Hospitals and Prisma Health, strengthening its presence in the urgent care industry. Despite rapid growth, WellStreet remains dedicated to delivering best-in-class quality and an exceptional patient experience, ensuring uncompromising care for each patient, one at a time. WellStreet is committed to adapting and innovating to meet the healthcare needs of tomorrow, always prioritizing the well-being of those it serves. About binx health binx health is a leading healthcare technology and diagnostics company that aims to improve patient access to STI diagnostics at the Point of Care. The Company works with a variety of health care entities who have a significant interest in delivering or facilitating improved access to critical STI diagnostics in-clinic. Their most recent achievement, the binx io, is an FDA-cleared, CLIA-waived, molecular PCR chlamydia and gonorrhea test. Male and female patients can receive lab-comparable test result in ~30 minutes which enables providers to implement a same day test & treatment model for patients. For more information, please visit
